Good one cgt,
There is also the 'feel safe factor' - if we go to phase3 trial in the us asap, then FDA have another string to their bow as 'eua' (emergency use authorization) could be given to Inavir should the need arise, as was the case with Relenza dispensed with the new Rotahaler,(while under Phase 1 safety study) in Europe during the pandemic.
